POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

FDA approves Johnson & Johnson's one-shot COVID-19 vaccine for emergency use

Christian Fernsby |
The U.S. Food and Drug Administration (FDA) on Saturday authorized Johnson & Johnson's COVID-19 vaccine for emergency use in the United States.

Article continues below




It is the third COVID-19 vaccine that has received the FDA's emergency use authorization in the country, following the first one developed by American drugmaker Pfizer in partnership with German company BioNTech, and the second one developed by American drugmaker Moderna.

It is also the first single dose COVID-19 vaccine available in the United States.

The new federal authorization allows Johnson & Johnson's vaccine to be distributed in the United States for use in individuals 18 years of age and older, according to the FDA.

The totality of the available data provides clear evidence that the vaccine may be effective in preventing COVID-19, the FDA said in a statement.

The data also shows that the known and potential benefits of the vaccine outweigh its known and potential risks, which supports the company's request for the vaccine's use in people 18 years of age and older, said the FDA.

"The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States," said Acting FDA Commissioner Janet Woodcock.

The approval came a day after a key FDA advisory committee recommended authorizing the vaccine for emergency use.

Unlike the two-shot dosing for the vaccines from Pfizer-BioNTech and Moderna, the Johnson & Johnson vaccine only requires one shot. Meanwhile, it does not require ultra-cold storage.

The United States remains the nation worst hit by the pandemic, with more than 28 million cases and over half a million deaths, according to the Center for Systems Science and Engineering at Johns Hopkins University.

U.S. President Joe Biden's national vaccination campaign aims to administer 100 million doses of two-stage coronavirus vaccines in his first 100 days in office.

Over 96 million vaccine doses have been distributed across the United States as of Saturday, and more than 72 million doses have been administered, the U.S. Centers for Disease Control and Prevention's data shows.


What to read next

Consumers remain highly skeptical of the vaccine
World-first COVID-19 alternating dose vaccine study launches in UK
Congo to deploy controversial Ebola vaccine